Vemurafenib, 99%, a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively

Name: Vemurafenib, 99%, a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively | 918504-65-1
Brand: J&K Chemical
SKU: JK1349108_25_MG
Price: 17.12 USD
Availability: OutOfStock

Cat. No JK1349108_25_MG

Vendor: J&K Chemical

Product Information

Product Name

Vemurafenib, 99%, a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively

Brand Name

J&K

Product Number

1349108

CAS

918504-65-1

Molecular Formula

C23H18ClF2N3O3S

Molecular Weight

489.92

SDS Document

View/Download

Certificate of Analysis (COA)

COA not found

General Information

Synonyms

N-(3-(5-(4-Chlorophenyl)-1H-pyrrolo2,3-Bpyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonaMide

PubChem CID

42611257

IUPAC Name

N-3-5-(4-chlorophenyl)-1H-pyrrolo2,3-bpyridine-3-carbonyl-2,4-difluorophenylpropane-1-sulfonamide

InChI Key

GPXBXXGIAQBQNI-UHFFFAOYSA-N

SMILES

CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F

Properties

Density

1.47

Melting Point

260-262

n20D

1.65

Safety Information

Storage Condition

Freezer -20℃

References Data Source From Pubchem

A colorectal cancer risk model based on cell adhesion-related genes for predicting prognosis and immunological features

Publication Name: Molecular genetics and genomics : MGG

Publication Date: 2026-03-04

DOI: 10.1007/s00438-026-02377-4

Charting the landscape of drug response and resistance with multiplexed ‘mosaic’ tumor models

Publication Name: Nature Cancer

Publication Date: 2026-03-03

DOI: 10.1038/s43018-026-01131-4

Harnessing mitophagy for melanoma: enhancing prognosis through immune activation

Publication Name: Archives of Dermatological Research

Publication Date: 2026-03-02

DOI: 10.1007/s00403-026-04567-x

Anaplastic thyroid carcinoma: Clinicopathologic and immunohistochemical study of 144 cases with special emphasis on the spectrum of histologic features

Publication Name: Virchows Archiv : an international journal of pathology

Publication Date: 2026-02-27

DOI: 10.1007/s00428-026-04456-8

Origin, diagnosis and treatment of periocular Histiocytic disorders– state-of-the-art review

Publication Name: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie

Publication Date: 2026-02-27

DOI: 10.1007/s00417-026-07164-w

Vemurafenib, 99%, a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively

Product Information

General Information

Properties

Safety Information

References Data Source From Pubchem

A colorectal cancer risk model based on cell adhesion-related genes for predicting prognosis and immunological features

Charting the landscape of drug response and resistance with multiplexed ‘mosaic’ tumor models

Harnessing mitophagy for melanoma: enhancing prognosis through immune activation

Anaplastic thyroid carcinoma: Clinicopathologic and immunohistochemical study of 144 cases with special emphasis on the spectrum of histologic features

Origin, diagnosis and treatment of periocular Histiocytic disorders– state-of-the-art review